Show simple item record

dc.contributor.authorYeral, Mahmut
dc.contributor.authorAytan, Pelin
dc.contributor.authorGungor, Burcu
dc.contributor.authorBoga, Can
dc.contributor.authorUnal, Ali
dc.contributor.authorKoc, Yener
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorBuyukkurt, Nurhilal
dc.contributor.authorEser, Bulent
dc.contributor.authorOzdogdu, Hakan
dc.date.accessioned2020-12-31T09:57:47Z
dc.date.available2020-12-31T09:57:47Z
dc.date.issued2020
dc.identifier.issn2152-2650en_US
dc.identifier.urihttp://hdl.handle.net/11727/5331
dc.description.abstractIn this multicenter retrospective study, we compared the efficacy and toxicity of BEAM (BCNU, etoposide, cytarabine, and melphalan) and MITO/MEL (mitoxantrone, melphalan) preparation regimens. The 3-year expected overall survival for the MIT/MEL and BEAM were 86.1% and 91.3%, respectively. The MITO/MEL seems to be as effective as the BEAM but has better tolerability in terms of pulmonary toxicity and may be used as an alternative option. Background: Approximately half of patients with relapsed chemosensitive disease achieve robust responses with BEAM (BCNU, etoposide, cytarabine, and melphalan) and autologous stem cell rescue. The scarcity of comparative studies further limits alternative treatment protocols, such as the MITO/MEL (mitoxantrone, melphalan) protocol. Patients and Methods: In this retrospective multicenter study, we compared the BEAM and MITO/MEL regimens used before autologous hematopoietic stem cell transplantation (ASCT) in terms of efficacy and side effects in patients with Hodgkin lymphoma. Data met international accreditation rules. Before ASCT, 108 patients received the MITO/MEL, and 34 patients received the BEAM. Results: The median follow-up time was 36 months in the MITO/MEL group (range, 3-178) and 23 months in the BEAM group (range, 4-99). After ASCT, the 3-year expected overall survival and disease-free survival rates were 86.1% and 86.1% for the MITO/MEL group and 91.3% and 76.5% for the BEAM group, respectively. Although 50% of patients developed febrile neutropenia attacks in the MITO/MEL group, this rate was 91.1% in the BEAM group. The grade II and higher rates of hepatic, renal, gastrointestinal, and cardiac toxicities were similar in both groups. However, the rate of pulmonary toxicity was determined to be 1.9% in the MITO/MEL group and 29.4% in the BEAM group (P < .001). Conclusion: The MITO/MEL conditioning regimen seems to be as effective as the BEAM regimen but has better tolerability in terms of pulmonary toxicity and may be used as an alternative option if necessary, depending on the comorbidity status of the patient.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.clml.2020.05.009en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutologous transplantationen_US
dc.subjectConditioningen_US
dc.subjectLymphomaen_US
dc.subjectOutcomeen_US
dc.subjectStem cellen_US
dc.titleA Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicityen_US
dc.typearticleen_US
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIAen_US
dc.identifier.volume20en_US
dc.identifier.issue10en_US
dc.identifier.startpage652en_US
dc.identifier.endpage660en_US
dc.identifier.wos000585113900019en_US
dc.identifier.scopus2-s2.0-85086916646en_US
dc.contributor.pubmedID32605899en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record